NegativeSPX4,017.771.30%Negative
NegativeIXIC11,393.811.96%Negative
NegativeDJI33,717.090.77%Negative
NegativeSTOXX454.400.17%Negative
PositiveFTSE7,784.870.25%Positive
PositiveN22527,442.360.03%Positive

Agenus Inc

AGEN.O

Official Data Partner

Latest Trade: trading lower2.55USD
Change; -0.08; 3.04%Negative

As of Jan 31 2023. Values delayed up to 15 minutes

Day Range: 2.55 - 2.68
52-Week Range: 1.25 - 3.37

Previous Close: 2.63
Open: 2.60
Volume: 3,451,569.00
3 Month Average Trading Volume: 90.97
Shares Out (Mil): 294.95
Market Cap: 744.72
Forward P/E: -3.41
Dividend Yield: 0.00

Key Statistics

1.6 mean rating - 5 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 0.00
Price To Sales (TTM): 8.28
Price To Book (Quarterly): 0.00
Price To Cash Flow (Per Share TTM): 0.00
Total Debt/Total Equity (Quarterly): 0.00
Long Term Debt/Equity (Quarterly): 0.00
Return On Investment (TTM): -82.84
Return On Equity (TTM): -51.73

2021 (millions USD)

About Agenus Inc (AGEN.O)

Company Information

Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. It is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.